tbuckley/cabot-search huggingface dataset:
Abstract #1528: Regulation of Wnt signaling by the nuclear pore complex
Authors: Miki Shitashige, Reiko Satow, Tesshi Yamada
Journal: Cancer Research (2009)

The Wnt signaling pathway plays important roles in embryogenesisand carcinogenesis. The Wnt signal inhibits the degradation of \#946;-catenin. Excess \#946;-catenin proteins form complexes with T-cell factor (TCF)/lymphoid enhancer factor (LEF) family DNA-binding proteins. The function of \#946;-catenin as a transcriptional co-activator of T-cell factor-4 (TCF-4) is crucial for colorectal carcinogenesis. However, \#946;-catenin has no nuclear localization signal, and the mechanisms by which \#946;-catenin is imported into the nucleus and forms a complex with the TCF-4 nuclear protein are poorly understood. Methods: Proteins of two colorectal cancer cell lines, HCT-116 and DLD1, were immunoprecipitated with anti-TCF-4 antibody and analyzed directly by nano-flow liquid chromatography and mass spectrometry. Results: TCF-4 interacted with a large variety of nuclear pore complex (NPC) proteins including Ran (ras-related nuclear protein), RanBP2 (Ran binding protein-2), and RanGAP1 (Ran GTPase-activating protein-1). The NPC protein RanBP2 functioned as the small ubiquitin-related modifier (SUMO) E3 ligase of TCF-4, and sumoylation of TCF-4 enhanced the interaction between TCF-4 and \#946;-catenin. The overexpression of NPC proteins increased the nuclear import of the \#946;-catenin protein and enhanced the transcriptional activity. NPC proteins increased the growth of colorectal cancer cells, whereas desumoylating sentrin-specific protease-2 (SENP2) inhibited it. The expression level of RanGAP1 was constantly increased in the clinical samples of colorectal adenoma and adenocarcinoma. Conclusions: Modification of proteins by SUMO is involved in a large variety of molecular processes including protein-protein interaction, subcellular localization, transcriptional activity, and protein stability/degradation. Through a comprehensive proteomics approach we revealed that TCF-4 was sumoylated by a NPC protein, RanBP2. The NPC is a large protein complex that spans the double lipid layer of the nuclear envelope. NPC functions as a novel regulator of Wnt signaling and is possibly involved in colorectal carcinogenesis. A new drug targeting the interactions of TCF-4 with NPC proteins as well as their sumoylation activity might be effective for suppressing aberrant Wnt signaling and the proliferation of colorectal cancer cells. Reference: 1. Shitashige et al., Gastroenterology, 134:1961-71, 2008.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 1528.
26129 A systematic review and meta-analysis of prognostic outcomes in cutaneous squamous cell carcinoma with and without perineural invasion
Authors: Kristen Clark, Shirleen Cheng, William Guo, Julia Miao, Jocellie Marquez, Marissa Ayasse, Jamie Saragossi, Evan Jones, Jordan Slutsky
Journal: Journal of the American Academy of Dermatology (2021)
Direction selectivity in retinal bipolar cell axon terminals
Authors: Akihiro Matsumoto, Weaam Agbariah, Stella Solveig Nolte, Rawan Andrawos, Hadara Levi, Shai Sabbah, Keisuke Yonehara
Journal: Neuron (2021)

The ability to encode the direction of image motion is fundamental to our sense of vision. Direction selectivity along the four cardinal directions is thought to originate in direction-selective ganglion cells (DSGCs) because of directionally tuned GABAergic suppression by starburst cells. Here, by utilizing two-photon glutamate imaging to measure synaptic release, we reveal that direction selectivity along all four directions arises earlier than expected at bipolar cell outputs. Individual bipolar cells contained four distinct populations of axon terminal boutons with different preferred directions. We further show that this bouton-specific tuning relies on cholinergic excitation from starburst cells and GABAergic inhibition from wide-field amacrine cells. DSGCs received both tuned directionally aligned inputs and untuned inputs from among heterogeneously tuned glutamatergic bouton populations. Thus, directional tuning in the excitatory visual pathway is incrementally refined at the bipolar cell axon terminals and their recipient DSGC dendrites by two different neurotransmitters co-released from starburst cells.
Sequential <scp>P‐GEMOX</scp> and radiotherapy for early‐stage extranodal natural killer/<scp>T‐</scp>cell lymphoma: A multicenter study
Authors: Yuchen Zhang, Shuyun Ma, Jun Cai, Yu Yang, Hongmei Jing, Yuerong Shuang, Zhigang Peng, Bingzong Li, Panpan Liu, Zhongjun Xia, Yi Xia, Yan Gao, Daoguang Chen, Jianyang Lin, Qihui Li, Shenghua Xu, Qingyuan Xu, Han Zhang, Huiqiang Huang, Qingqing Cai
Journal: American Journal of Hematology (2021)

Abstract Extranodal natural killer/T‐cell lymphoma, nasal‐type (ENKTL) is a distinct subtype of non‐Hodgkin lymphoma and most of the patients presented localized disease. Combined modality therapy (CMT), namely chemotherapy combined with radiotherapy, has been recommended for patients with early‐stage ENKTL. However, the optimal CMT has not been fully clarified. This study reports the efficacy and toxicity of sequential P‐GEMOX (pegaspargase, gemcitabine and oxaliplatin) and radiotherapy in a large Chinese cohort comprising of 202 patients diagnosed with early‐stage ENKTL from six medical centers. The observed best overall response rate was 96.0% and 168 (83.2%) patients achieved complete remission. With a median follow‐up of 44.1 months, the 3‐year progression‐free survival (PFS) and overall survival (OS) were 74.6% and 85.2%, respectively. Multivariate analysis suggested that extensive primary tumor (PFS, hazard ratio [HR] 3.660, 95% CI 1.820–7.359, p &lt; 0.001; OS, HR 3.825, 95% CI 1.442–10.148, p = 0.007) and Eastern Cooperative Oncology Group performance status ≥ 2 (PFS, 3.042, 95% CI 1.468–6.306, p = 0.003; OS, HR 3.983, 95% CI 1.678–9.457, p = 0.02) were independent prognostic factors for survival outcomes. Among the established prognostic models for ENKTL, the nomogram‐revised risk index model had optimal prognostic risk stratification ability (PFS, p &lt; 0.001; OS, p &lt; 0.001) and relatively balanced population distribution. The adverse events of this CMT were well‐tolerated and manageable. In conclusion, sequential P‐GEMOX and radiotherapy showed favorable efficacy with acceptable toxicity, and could be an effective treatment option for early‐stage ENKTL patients.
Allan C Prentice
Authors: Stuart Scott
Journal: BMJ (2021)

Allan C Prentice spent his early years in Shetland and Edinburgh, before attending Madras College in St Andrews for his secondary education. He attended Dundee University, graduating in 1982. After hospital and general practice experience he joined Offshore Medical Support (OMS) in Aberdeen in August 1988 in an approved training post for occupational medicine, under the supervision of W J Gunnyeon, obtaining his …
SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Authors: H. Chung, K. Lee, W. Kim, J. Gainor, N. Lakhani, L. Chow, W. Messersmith, P. Fanning, P. Squifflet, F. Jin, A. Forgie, H. Wan, J. Pons, S. Randolph, P. LoRusso
Journal: Annals of Oncology (2021)
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
Authors: S. Schrodi, M. Braun, A. Andrulat, N. Harbeck, S. Mahner, M. Kiechle, E. Klein, A. Schnelzer, C. Schindlbeck, I. Bauerfeind, G. Schubert-Fritschle, V. Nekljudova, D. Mayr, W. Weichert, C. Denkert, S. Loibl, J. Engel
Journal: Annals of Oncology (2021)

Guideline recommendations for the treatment of breast cancer with low hormone receptor (HR) expression (1%-9%) are ambiguous and several studies showed more similarities with HR-negative tumors than with HR strongly positive tumors (≥10%). We used a population-based 15-year cohort to compare patient characteristics and outcome of HR low positive tumors with HR-negative and HR strongly positive tumors, respectively.A total of 38 560 women diagnosed with early invasive breast cancer between 2004 and 2018 within the scope of the Munich Cancer Registry with 4.9 million inhabitants were included. Descriptive analyses of prognostic factors, treatment, and outcome analyses using the Kaplan-Meier method; cumulative incidence in consideration of competing risks; and multivariate analyses (Cox regression and Fine-Gray model) were conducted. Endpoints were time to local recurrence (TTLR), time to lymph node recurrence (TTLNR), time to metastasis (TTM), overall survival (OS), and relative survival (RS).A total of 861 patients (2%) had HR low positive, 4862 (13%) HR-negative, and 32 837 (85%) HR strongly positive tumors. Within the HER2-negative cohort (n = 33 366), survival of HR low positive tumors was significantly worse than that of HR strongly positive tumors [OS hazard ratio 0.66 (95% confidence interval 0.55-0.78)], whereas between HR low positive and HR-negative tumors no significant survival difference could be detected [OS hazard ratio 0.93 (95% confidence interval 0.78-1.11)]. TTLR, TTLNR, and TTM showed similar results. By contrast, within the HER2-positive cohort (n = 5194), no statistically significant differences between the three HR groups could be detected in multivariate analyses.Current definitions for HR positivity and its clinical relevance should be reconsidered. Patients with HR low positive/HER2-negative tumors could be regarded and treated similar to patients with triple-negative tumors.
O-6 Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial
Authors: N. Takahashi, N. Izawa, K. Nishio, T. Masuishi, H. Shoji, Y. Yamamoto, T. Matsumoto, K. Sugiyama, T. Kajiwara, K. Kawakami, N. Aomatsu, H. Kawakami, T. Esaki, Y. Narita, H. Hara, Y. Horie, N. Boku, K. Miura, T. Moriwaki, M. Shimokawa, T. Nakajima, K. Muro
Journal: Annals of Oncology (2021)
Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
Authors: Ai-Min Wu, Catherine Bisignano, Spencer L James, Gdiom Gebreheat Abady, Aidin Abedi, Eman Abu-Gharbieh, Robert Kaba Alhassan, Vahid Alipour, Jalal Arabloo, Malke Asaad, Wondwossen Niguse Asmare, Atalel Fentahun Awedew, Maciej Banach, Srikanta K Banerjee, Ali Bijani, Tesega Tesega Mengistu Birhanu, Srinivasa Rao Bolla, Luis Alberto Cámera, Jung-Chen Chang, Daniel Youngwhan Cho, Michael T Chung, Rosa A S Couto, Xiaochen Dai, Lalit Dandona, Rakhi Dandona, Farshad Farzadfar, Irina Filip, Florian Fischer, Artem Alekseevich Fomenkov, Tiffany K Gill, Bhawna Gupta, Juanita A Haagsma, Arvin Haj-Mirzaian, Samer Hamidi, Simon I Hay, Irena M Ilic, Milena D Ilic, Rebecca Q Ivers, Mikk Jürisson, Rohollah Kalhor, Tanuj Kanchan, Taras Kavetskyy, Rovshan Khalilov, Ejaz Ahmad Khan, Maseer Khan, Cameron J Kneib, Vijay Krishnamoorthy, G Anil Kumar, Narinder Kumar, Ratilal Lalloo, Savita Lasrado, Stephen S Lim, Zichen Liu, Ali Manafi, Navid Manafi, Ritesh G Menezes, Tuomo J Meretoja, Bartosz Miazgowski, Ted R Miller, Yousef Mohammad, Abdollah Mohammadian-Hafshejani, Ali H Mokdad, Christopher J L Murray, Mehdi Naderi, Mukhammad David Naimzada, Vinod C Nayak, Cuong Tat Nguyen, Rajan Nikbakhsh, Andrew T Olagunju, Nikita Otstavnov, Stanislav S Otstavnov, Jagadish Rao Padubidri, Jeevan Pereira, Hai Quang Pham, Marina Pinheiro, Suzanne Polinder, Hadis Pourchamani, Navid Rabiee, Amir Radfar, Mohammad Hifz Ur Rahman, David Laith Rawaf, Salman Rawaf, Mohammad Reza Saeb, Abdallah M Samy, Lidia Sanchez Riera, David C Schwebel, Saeed Shahabi, Masood Ali Shaikh, Amin Soheili, Rafael Tabarés-Seisdedos, Marcos Roberto Tovani-Palone, Bach Xuan Tran, Ravensara S Travillian, Pascual R Valdez, Tommi Juhani Vasankari, Diana Zuleika Velazquez, Narayanaswamy Venketasubramanian, Giang Thu Vu, Zhi-Jiang Zhang, Theo Vos
Journal: The Lancet Healthy Longevity (2021)

Bone fractures are a global public health issue; however, to date, no comprehensive study of their incidence and burden has been done. We aimed to measure the global, regional, and national incidence, prevalence, and years lived with disability (YLDs) of fractures from 1990 to 2019.
Mobility Assessment in Older Adults
Authors: Kirstyn James, Andrea Wershof Schwartz, Ariela R. Orkaby
Journal: New England Journal of Medicine (2021)

A change in mobility or walking speed may indicate frailty and a risk of falls, especially in an older person. This video demonstrates a focused mobility assessment, including the four-stage balance test, a gait-speed measurement test, and the chair stand test, in which the patient is asked to stand up from a chair.
Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma
Authors: Caroline Boursier, Mathieu Perrin, Manon Bordonne, Arnaud Campidelli, Antoine Verger
Journal: Clinical Nuclear Medicine (2021)

18F-FDG PET/CT imaging series were acquired on a 64-year-old woman with refractory diffuse large B lymphoma to monitor chimeric antigen receptor (CAR) T-cell therapy. Because of a clinical deterioration, 18F-FDG PET/CT performed 8 days after CAR T-cell therapy suggested an early flare-up phenomenon with new lymph node involvement, lymph node progression while a decrease in metabolic tumor volume. The 18F-FDG PET/CT 1 month after CAR T-cell therapy confirmed this hypothesis. Pseudoprogression in solid tumors treated by immunotherapy has generally been reported later after treatment.
Extracellular Matrix Stiffness Regulates DNA Methylation by PKC<i>α</i>‐Dependent Nuclear Transport of DNMT3L (Adv. Healthcare Mater. 16/2021)
Authors: Xin‐Bin Zhao, Yun‐Ping Chen, Min Tan, Lan Zhao, Yuan‐Yuan Zhai, Yan‐Ling Sun, Yan Gong, Xi‐Qiao Feng, Jing Du, Yu‐Bo Fan
Journal: Advanced Healthcare Materials (2021)

Extracellular Matrix Stiffness In article number 2100821 by Jing Du, Yu-Bo Fan, and co-workers, extracellular matrix (ECM) stiffness has profound effects on the regulation of cell functions. Stiff ECM enhances DNA methylation of pluripotent genes by the nuclear transport of DNA methyltransferase 3-like binding to Nanog promoter in mouse embryonic stem cells (mESCs). DNA methylation is a novel target for the mechanical sensing mechanism during mESCs–ECM interactions.
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
Authors: Russell K Pachynski, Chihiro Morishima, Russell Szmulewitz, Lauren Harshman, Leonard Appleman, Paul Monk, Rhonda L Bitting, Omer Kucuk, Frederick Millard, John D Seigne, Steven P Fling, Holden T Maecker, Caroline Duault, Nirasha Ramchurren, Bruce Hess, Leonard D’Amico, Andreanne Lacroix, Judith C Kaiser, Michel Morre, Anne Grégoire, Martin Cheever, Evan Y Yu, Lawrence Fong
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell development and proliferation, would augment and prolong antigen-specific immune responses against both PA2024 (the immunogen for sip-T) and prostatic acid phosphatase (PAP). Methods Fifty-four patients with mCRPC treated with sip-T were subsequently enrolled and randomized 1:1 into observation (n=26) or IL-7 (n=28) arms of a phase II clinical trial ( NCT01881867 ). Recombinant human (rh) IL-7 (CYT107) was given weekly×4. Immune responses were evaluated using flow cytometry, mass cytometry (CyTOF), interferon (IFN)-γ ELISpot, 3 H-thymidine incorporation, and ELISA. Results Treatment with rhIL-7 was well tolerated. For the rhIL-7-treated, but not observation group, statistically significant lymphocyte subset expansion was found, with 2.3–2.6-fold increases in CD4+T, CD8+T, and CD56 bright NK cells at week 6 compared with baseline. No significant differences in PA2024 or PAP-specific T cell responses measured by IFN-γ ELISpot assay were found between rhIL-7 and observation groups. However, antigen-specific T cell proliferative responses and humoral IgG and IgG/IgM responses significantly increased over time in the rhIL-7-treated group only. CyTOF analyses revealed pleiotropic effects of rhIL-7 on lymphocyte subsets, including increases in CD137 and intracellular IL-2 and IFN-γ expression. While not powered to detect clinical outcomes, we found that 31% of patients in the rhIL-7 group had prostate specific antigen (PSA) doubling times of &gt;6 months, compared with 14% in the observation group. Conclusions Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56 bright natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.
自己拡張可能(Radius)ステント埋め込みによる慢性血管リモデリングの予測因子としての前インターベンション障害特性
Authors: Watanabe K, Matsushita T, Kondou M, Okada T, Mutoh M, Yamada T, Tani T, Iwata K, Toyama J
Journal: Circulation (2003)
27535 Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: 104-week data from a phase 2 study
Authors: John E. Harris, Amit G. Pandya, Mark Lebwohl, Pearl Grimes, Alice B. Gottlieb, Howard L. Sofen, Angela Y. Moore, Kathleen Butler, Fiona Kuo, Kang Sun, David Rosmarin
Journal: Journal of the American Academy of Dermatology (2021)
Intestinal virome and therapeutic potential of bacteriophages in liver disease
Authors: Cynthia L. Hsu, Yi Duan, Derrick E. Fouts, Bernd Schnabl
Journal: Journal of Hepatology (2021)

Humans harbour a large quantity of microbes in the intestinal tract and have evolved symbiotic relationships with many of them. However, several specific bacterial pathobionts are associated with liver disease pathogenesis. Although bacteriophages (phages) and eukaryotic viruses (collectively known as “the virome”) outnumber bacteria and fungi in the intestine, little is known about the intestinal virome in patients with liver disease. As natural predators of bacteria, phages can precisely edit the bacterial microbiota. Hence, there is interest in using them to target bacterial pathobionts in several diseases, including those of the liver. Herein, we will summarise changes in the faecal virome associated with fatty liver diseases and cirrhosis, and describe the therapeutic potential of phages and potential challenges to their clinical application.
Dysregulation of microRNAs in metal-induced angiogenesis and carcinogenesis
Authors: Lin Wang, Ling-Zhi Liu, Bing-Hua Jiang
Journal: Seminars in Cancer Biology (2021)

MicroRNAs (miRNAs) are small endogenous non-coding RNAs that regulate cancer initiation, development, angiogenesis, and therapeutic resistance. Metal exposure widely occurs through air, water, soil, food, and industrial contaminants. Hundreds of millions of people may have metal exposure associated with toxicity, serious health problems, and cancer occurrence. Metal exposure is found to induce oxidative stress, DNA damage and repair, and activation of multiple signaling pathways. However, molecular mechanisms of metal-induced carcinogenesis remain to be elucidated. Recent studies demonstrated that the exposure of metals such as arsenic, hexavalent chromium, cadmium, and nickel caused dysregulation of microRNAs that are implicated to play an important role in cell transformation, tumor growth and angiogenesis. This review focuses on the recent studies that show metal-induced miRNA dysregulation and underlined mechanisms in cell malignant transformation, angiogenesis and tumor growth.
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13
Authors: Costanza Zanetti, Rahul Kumar, Joscha Ender, Parimala S. Godavarthy, Mark Hartmann, Joschka Hey, Kersten Breuer, Eva S. Weissenberger, Valentina R. Minciacchi, Christina Karantanou, Zhaohui Gu, Kathryn G. Roberts, Markus Metzler, Wendy Stock, Charles G. Mullighan, Clara D. Bloomfield, Natalie Filmann, Katrin Bankov, Sylvia Hartmann, Robert P. Hasserjian, Antony F. Cousins, Christina Halsey, Christoph Plass, Daniel B. Lipka, Daniela S. Krause
Journal: Blood (2021)
26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to &lt;12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)
Authors: Michael J. Cork, Diamant Thaçi, Lawrence Eichenfield, Peter D. Arkwright, Zhen Chen, Dimittri Delevry, John T. O’Malley, Ashish Bansal
Journal: Journal of the American Academy of Dermatology (2021)
Oral glucose tolerance test performance and multidisciplinary team approach improve secondary prevention measures in non-diabetic coronary patients
Authors: Jesús María de la Hera Galarza, Ernesto Hernández Martín, José Miguel Vegas Valle, Ramón Suárez Arias, Pablo Avanzas Fernández, José Manuel García Ruiz, Ignacio Manuel Lozano Martínez-Luengas, Amelia Carro Hevia, Elías Delgado Álvarez, César Morís de la Tassa
Journal: Circulation (2008)
26839 Dupilumab with topical corticosteroids results in rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across all anatomic regions over 52 weeks
Authors: Andrew Blauvelt, Marjolein de Bruin-Weller, Melinda Gooderham, David M. Pariser, Eric L. Simpson, Takafumi Etoh, Zhen Chen, Brad Shumel
Journal: Journal of the American Academy of Dermatology (2021)
Similarities and differences in concepts of mental life among adults and children in five cultures
Authors: Kara Weisman, Cristine H. Legare, Rachel E. Smith, Vivian A. Dzokoto, Felicity Aulino, Emily Ng, John C. Dulin, Nicole Ross-Zehnder, Joshua D. Brahinsky, Tanya Marie Luhrmann
Journal: Nature Human Behaviour (2021)
27409 Tissue ulceration and necrosis secondary to extravasation of mitomycin chemotherapy
Authors: Karolina Mieczkowska, Parth Patel, Bijal Amin, Adnan Mir, Rachel Blasiak, Ranon E. Mann, Shalom Kalnicki, Yevgeniy Balagula, Beth N. McLellan
Journal: Journal of the American Academy of Dermatology (2021)
Bispecific Antibodies in Multiple Myeloma: Present and Future
Authors: Guido Lancman, Dahniel L. Sastow, Hearn J. Cho, Sundar Jagannath, Deepu Madduri, Samir S. Parekh, Shambavi Richard, Joshua Richter, Larysa Sanchez, Ajai Chari
Journal: Blood Cancer Discovery (2021)

Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach designed to bind antigens on malignant plasma cells and cytotoxic immune effector cells. Early-phase clinical trials targeting B-cell maturation antigen (BCMA), GPRC5D, and FcRH5 have demonstrated a favorable safety profile, with mainly low-grade cytokine release syndrome, cytopenias, and infections. Although dose escalation is ongoing in several studies, early efficacy data show response rates in the most active dose cohorts between 61% and 83% with many deep responses; however, durability remains to be established. Further clinical trial data are eagerly anticipated.Overall survival of triple-class refractory multiple myeloma remains poor. Bispecific antibodies are a novel immunotherapeutic modality with a favorable safety profile and impressive preliminary efficacy in heavily treated patients. Although more data are needed, bispecifics will likely become an integral part of the multiple myeloma treatment paradigm in the near future. Studies in earlier lines of therapy and in combination with other active anti-multiple myeloma agents will help further define the role of bispecifics in multiple myeloma.